Trial Profile
A randomized, double-blind, placebo-controlled, three arm study to evaluate the effects of tolterodine ER [extended release] 4 mg vs. placebo vs. oxybutynin ER on memory and other cognitive abilities in elderly subjects.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jan 2021
Price :
$35
*
At a glance
- Drugs Tolterodine (Primary) ; Oxybutynin
- Indications Overactive bladder
- Focus Pharmacodynamics
- Sponsors Pfizer
- 06 Jul 2007 Status change from recruiting to completed
- 05 Jan 2007 New trial record.